Calvin Ho to Treatment Outcome
This is a "connection" page, showing publications Calvin Ho has written about Treatment Outcome.
Connection Strength
0.150
-
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2025 Nov; 84(11):1888-1899.
Score: 0.053
-
Benralizumab does not elicit therapeutic effect in patients?with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J Dermatol. 2024 Jul 16; 191(2):187-199.
Score: 0.049
-
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary. Immunotherapy. 2024; 16(10):641-648.
Score: 0.048